Amneal Pharmaceuticals, Inc.
AMRX · Price history
Price at last available close
$21.12
+$0.62 (+3.04%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Amneal Pharmaceuticals, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE.
How they make money
Amneal Pharmaceuticals operates as a specialty pharmaceutical company that develops, manufactures, and distributes generic and branded medicines. It generates revenue through three primary segments: Generics (Affordable Medicines), Specialty (branded neurology and endocrinology products), and AvKARE (wholesale distribution of pharmaceuticals and medical products to federal and institutional customers).
Products & services
The company provides a portfolio of generic and specialty pharmaceutical products, including branded treatments for Parkinson’s disease and migraine, as well as medical and surgical supplies distributed through its AvKARE segment.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Disclosed major customers
- Customer ASource
Customer concentration
For the year ended December 31, 2025, Customer A accounted for 25% of the company's net revenues.
Suppliers, materials & equipment
- Active Pharmaceutical Ingredient (API) suppliers — The company relies on various third-party suppliers for raw materials and active pharmaceutical ingredients; specific supplier names are not disclosed.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
25
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
41
Weak
Financial Strength
53
Business Quality / Moat
26
Management
57
Growth Quality
36
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
29
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
36/100
Building Historical Record
Model Score 36/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Elevated debt risk
- •M&A headline · Aug 10, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for AMRX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AMRX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is AMRX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is AMRX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify AMRX's current valuation?
Essential Investment Snapshot
Wall Street Score
25
Opportunity Score
29
Market Cap
$6.77B
P/E Ratio
40.5
EPS
$0.50
52-Week High
$21.18
52-Week Low
$9.56
Beta
1.24
Intrinsic Value
$15.09
Analyst Target
$23.00
Shares Outstanding
324.8M
Total Revenue
$3.12B
Total Debt
$2.79B
Dividend
No current dividend
Liquidation Value / Share
$0.36
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AMRX
Detected from reported data — verify before acting.Elevated debt risk
Negative shareholder equity • Interest coverage is below 2x • Cash covers less than 20% of total debt
M&A headline · Aug 10, 2026
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on AMRX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Diversified portfolio across generic and specialty segments.
- +Vertical integration in manufacturing and distribution.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Interest coverage is below 2x.
- −Cash covers less than 20% of total debt.
- −High customer concentration.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
26
Sep 8, 2026
Change
-1.0
points
Current Score
25
Oct 1, 2026
Category Changes
AMRX decreased 1 points because Capital declined by 2 points, Valuation declined by 5.9 points.
Negative Contributors
- − Capital declined by 2 points
- − Valuation declined by 5.9 points
Projected Score
Projected Score
29
Projected Change
+4.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$21.20
Model Intrinsic Value
$15.09
Difference
+$6.11
+40.5% vs IV
Margin of Safety
-40.5%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.12B | $3.02B | $2.79B | $2.39B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $1.89B | $1.88B | $1.77B | $1.53B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.23B | $1.14B | $1.02B | $863.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $177.7M | $186.2M | $190.7M | $194.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $571.9M | $526.8M | $476.4M | $429.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $822.5M | $713.0M | $771.1M | $659.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $652.2M | $603.9M | $439.8M | $500.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $403.2M | $423.1M | $249.3M | $204.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $227.5M | $241.1M | $258.6M | $210.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $201.2M | $139.2M | -$55.0M | -$40.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$14.1M | $11.3M | $18.9M | $8.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $157.4M | $72.1M | -$116.9M | -$84.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $0.50 | $0.23 | $-0.38 | $-0.48 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 319M | 313M | 309M | 175M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 328M | 325M | 309M | 176M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$796.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.18
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+8.1%
Cash Change
+57.2%
Margin Change
+4.1 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 9.9%. EPS increased 159.0%. Cash increased 57.2%. Total debt increased 8.1%. Net income margin improved by 4.1 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericNews
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50
Rumor Mill · AMRX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial